Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk

NCT04258371 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT04258371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04258371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Unknown status
Start date
February 10, 2020
Completion date
December 31, 2023
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular risk factor